Skip to main content
Moleculin Biotech, Inc. logo

Moleculin Biotech, Inc. — Investor Relations & Filings

Ticker · MBRX ISIN · US60855D2009 LEI · 549300IB1TLJZCHEO353 US Manufacturing
Open in API
Filings indexed 783 across all filing types
Latest filing 2026-05-29 Regulatory Filings
Country US United States of America
Listing US MBRX

About Moleculin Biotech, Inc.

https://moleculin.com/

Moleculin Biotech, Inc. is a late-stage clinical pharmaceutical company focused on developing a portfolio of therapeutic candidates for highly resistant cancers and viruses. The company's lead drug candidate is Annamycin, a next-generation liposomal anthracycline designed to be non-cardiotoxic and to circumvent multidrug resistance. Annamycin is being advanced in a pivotal Phase 3 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company's development pipeline also includes other drug candidates targeting hard-to-treat tumors.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 85% confidence The document is an SEC Form 8-K Current Report under the Exchange Act – a routine regulatory filing disclosing a press release (Exhibit 99.1) regarding ASCO data. It does not present full financial statements or earnings details itself but simply furnishes a press release. This falls under the generic “Regulatory Filings” category (RNS) rather than a specific financial report or announcement like an earnings release or annual report.
2026-05-29 English
FORM 8-K
Investor Presentation Classification · 90% confidence The document is a Form 8-K current report under Item 7.01 (Regulation FD Disclosure) which furnishes an investor presentation as Exhibit 99.1 dated May 2026. It is not a full financial report but an announcement and embedding of a corporate Investor Presentation. Therefore, the filing aligns with the “Investor Presentation” category.
2026-05-26 English
FORM 8-K
Regulatory Filings Classification · 91% confidence The document is a U.S. SEC Form 8-K current report (regulation FD disclosure), not a full financial report or earnings release, and contains no substantive financial statements or executive changes. It is a general regulatory filing disclosing a press release and an abstract. This does not fit specific categories like Earnings Release, Proxy, or Annual/Interim Reports, so it falls under the general Regulatory Filings (RNS) category.
2026-05-22 English
FORM 8-K
Earnings Release Classification · 85% confidence The document is a Form 8-K “Item 2.02 Results of Operations and Financial Condition,” reporting that the company issued a press release with its quarterly financial results. It does not include full financial statements but serves as the initial announcement of periodical financial results. This matches the definition of an Earnings Release (ER). Q1 2026
2026-05-15 English
FORM 10-Q
Interim / Quarterly Report Q1 2026
2026-05-14 English
8-K - Moleculin Biotech, Inc. (0001659617) (Filer)
Regulatory Filings Classification · 84% confidence The document is a U.S. SEC Form 8-K “Current Report,” providing a Regulation FD disclosure and attaching a press release. It does not contain substantive financial statements or fall under specialized categories such as earnings release, management discussion, M&A, or other specific filings. As a general SEC current report disclosing non-financial press release information, it best fits the fallback category “Regulatory Filings” (RNS).
2026-05-13 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.